Ceralasertib (AZD6738): A Comprehensive Monograph on a Leading ATR Kinase Inhibitor in Oncology

Executive Summary

Ceralasertib (AZD6738) is an investigational, orally bioavailable, small molecule inhibitor of the Ataxia Telangiectasia and Rad3-related (ATR) kinase, under development by AstraZeneca. As a central component of the DNA Damage Response (DDR) pathway, ATR is critical for maintaining genomic stability, particularly in response to replication stress—a hallmark of many cancers. Ceralasertib functions as a potent and highly selective ATP-competitive inhibitor of ATR, leading to the abrogation of cell-cycle checkpoints, disruption of DNA repair, and ultimately, selective apoptosis in cancer cells. Its therapeutic rationale is twofold: inducing synthetic lethality in tumors with pre-existing DDR defects (such as ATM loss) and sensitizing tumors to DNA-damaging agents and other therapies.

The preclinical profile of Ceralasertib is robust, demonstrating significant antineoplastic activity both in vitro across numerous cancer cell lines and in vivo in xenograft models. This activity is particularly pronounced in tumors with ATM deficiency and is enhanced when combined with chemotherapy, radiotherapy, and PARP inhibitors. The clinical development program for Ceralasertib is extensive and multifaceted, evaluating the agent as both a monotherapy and a versatile combination partner. The Phase I PATRIOT trial established its monotherapy safety profile and recommended Phase II dose (RP2D), revealing durable responses in biomarker-selected patients with advanced solid tumors, particularly those with ARID1A mutations.

Combination therapy trials have shown significant promise. When combined with chemotherapy agents like paclitaxel, Ceralasertib has yielded high response rates in immunotherapy-refractory melanoma. Most notably, its combination with the PD-L1 inhibitor durvalumab has produced compelling efficacy signals in advanced gastric cancer and non-small cell lung cancer (NSCLC). These findings have culminated in the initiation of the pivotal Phase III LATIFY trial in NSCLC, which could establish a new standard of care in the post-immunotherapy setting.

The safety profile of Ceralasertib is well-characterized, with the primary dose-limiting toxicities being hematologic in nature, including thrombocytopenia, anemia, and neutropenia. These adverse events are considered on-target effects and are manageable through intermittent dosing schedules, which have been shown to be better tolerated than continuous administration. As a leading candidate in the competitive landscape of ATR inhibitors, Ceralasertib is distinguished by its advanced stage of clinical development and the strength of its immuno-oncology combination data, positioning it as a potentially transformative agent in oncology.

1.0 Introduction: Targeting the DNA Damage Response with Ceralasertib

1.1 The Role of the ATR Kinase in Genomic Integrity and Cancer

The integrity of the human genome is under constant threat from both endogenous and environmental sources of DNA damage. To counteract this, cells have evolved a complex and highly integrated network of signaling pathways collectively known as the DNA Damage Response (DDR).[1] This network is responsible for detecting DNA lesions, signaling their presence, and mediating their repair, thereby preventing the accumulation of mutations that can lead to diseases such as cancer.

A central coordinator of the DDR is the Ataxia Telangiectasia and Rad3-related (ATR) protein, a large serine/threonine kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family.[1] ATR functions as a master regulator of the cellular response to a specific type of genotoxic insult known as replication stress, which is characterized by the stalling or slowing of DNA replication forks and the exposure of single-stranded DNA (ssDNA).[3] Upon recruitment to sites of ssDNA coated with Replication Protein A (RPA), ATR is activated and phosphorylates a multitude of downstream substrates, most notably the checkpoint kinase 1 (CHK1).[5] The activation of the ATR-CHK1 signaling cascade initiates a series of critical cellular events, including the stabilization of stalled replication forks to prevent their collapse into lethal double-strand breaks, the implementation of intra-S and G2/M cell-cycle checkpoints to provide time for repair, and the direct promotion of DNA repair pathways.[3]

1.2 The Therapeutic Rationale for ATR Inhibition

While the ATR pathway is essential for the survival of normal cells, it is often co-opted by cancer cells to withstand their own chaotic biology. Malignant transformation is frequently driven by oncogenes (e.g., MYC, mutant RAS) that promote uncontrolled proliferation, leading to high levels of intrinsic replication stress.[2] Furthermore, many cancers acquire defects in other key DDR pathways, such as the loss of Ataxia Telangiectasia Mutated (ATM) kinase function, which primarily responds to double-strand breaks.[2] This confluence of high replication stress and compromised DDR machinery renders cancer cells critically dependent on the remaining ATR pathway for their survival and continued proliferation.[1]

This dependency creates a profound therapeutic vulnerability. The inhibition of ATR is hypothesized to be selectively lethal to cancer cells while largely sparing normal, healthy cells that have lower levels of replication stress and intact alternative DDR pathways. This principle, known as synthetic lethality, forms the cornerstone of the therapeutic rationale for developing ATR inhibitors as monotherapy agents, particularly for tumors with defined DDR defects like ATM deficiency.[1]

Beyond monotherapy, ATR inhibition holds immense promise as a combination strategy. By disabling a primary mechanism of DNA repair, ATR inhibitors can dramatically sensitize cancer cells to the effects of conventional DNA-damaging treatments, including chemotherapy (e.g., platinum agents) and ionizing radiation.[5] This approach aims to overcome both intrinsic and acquired resistance to these foundational cancer therapies.

1.3 Ceralasertib: An Overview of a Potent and Selective ATR Inhibitor

Ceralasertib, also known by its code name AZD6738, is an investigational, orally bioavailable, small molecule developed by AstraZeneca as a potent and selective inhibitor of the ATR kinase.[5] It was designed to capitalize on the therapeutic vulnerabilities created by ATR dependency in cancer. The extensive clinical development program for Ceralasertib reflects a sophisticated, multi-pronged strategy. It is being evaluated not only as a monotherapy for biomarker-selected populations but also as a versatile combination partner with cytotoxic chemotherapy, targeted therapies like PARP inhibitors, and, most notably, immuno-oncology agents.[10] This broad investigational scope suggests a high degree of confidence in its underlying mechanism and a strategic effort to position Ceralasertib as a potential backbone therapy capable of enhancing the efficacy of multiple pillars of modern cancer treatment. Success across these diverse settings would establish ATR inhibition as a fundamental therapeutic approach in oncology.

2.0 Molecular Profile and Physicochemical Properties

2.1 Chemical Structure and Identifiers

Ceralasertib is a complex heterocyclic compound belonging to the morpholino-pyrimidine chemical class, distinguished by the presence of a chiral sulfoximine moiety.[1] Its precise chemical identity is defined by a comprehensive set of identifiers used across chemical, pharmaceutical, and regulatory databases. These identifiers are crucial for ensuring accuracy in research, clinical trials, and scientific communication. A consolidated list of these key identifiers is provided in Table 1.

Table 1: Key Chemical and Drug Identifiers for Ceralasertib

Identifier Type	Value	Source(s)
Drug Name	Ceralasertib	5
Code Name	AZD6738, AZD-6738	5
DrugBank ID	DB14917	5
CAS Number	1352226-88-0	5
Type	Small Molecule	5
Molecular Formula	C20​H24​N6​O2​S	5
Molecular Weight	412.51 g/mol	6
IUPAC Name	imino-methyl--2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane	5
SMILES	C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)(=N)(=O)C)C4=CN=CC5=C4C=CN5	5
InChIKey	DTTJKLNXNZAVSM-JYCIKRDWSA-N	5
UNII	85RE35306Z	5
NCI Thesaurus Code	C111993	5

2.2 Physical and Chemical Characteristics

In its solid state, Ceralasertib presents as a white powder.[6] Its solubility characteristics are critical for its formulation as an oral therapeutic and for its use in preclinical research. It is soluble in laboratory organic solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and ethanol, typically at concentrations around 30 mg/mL.[8] Its solubility in aqueous solutions is significantly lower, as evidenced by its solubility of 0.16 mg/mL in an ethanol:PBS buffer (pH 7.2) at a 1:5 ratio.[8] The development program has focused on the specific chiral molecule (free base, CAS 1352226-88-0), although other forms, such as a formate salt and a racemic mixture, have also been synthesized for research purposes.[6] The molecule is stable under ambient shipping conditions, facilitating its global distribution for clinical trials.[6]

3.0 Pharmacodynamics: Mechanism of Action

3.1 Potency, Selectivity, and Target Engagement

Ceralasertib is a highly potent and selective, ATP-competitive inhibitor of the ATR kinase.[11] Its potency against the isolated ATR enzyme is exceptionally high, with a reported half-maximal inhibitory concentration (

IC50​) of 1 nM.[6] This potent enzymatic inhibition translates effectively into a cellular context, where Ceralasertib inhibits the ATR-dependent phosphorylation of its primary downstream substrate, CHK1, with an

IC50​ of 74 nM.[8]

A defining feature of Ceralasertib is its remarkable selectivity. In broad kinase panel screening against over 442 kinases, Ceralasertib showed no significant inhibition (>50% inhibition) at a concentration of 1 µM.[16] Crucially, it demonstrates a wide margin of selectivity against other members of the PIKK family, which share structural homology with ATR. The cellular

IC50​ values for inhibition of ATM, DNA-dependent protein kinase (DNA-PK), and mammalian target of rapamycin (mTOR) are all greater than 5 µM, concentrations that are well above those required for effective ATR inhibition.[2] This high degree of selectivity is critical for minimizing off-target toxicities and contributes to a more favorable therapeutic index.

3.2 Downstream Cellular Effects: From CHK1 Inhibition to Apoptosis

The primary pharmacodynamic effect of Ceralasertib is the blockade of ATR-mediated signaling.[5] By preventing the phosphorylation and activation of CHK1, Ceralasertib effectively dismantles the DNA damage checkpoint that holds cells in the G2/M phase of the cell cycle.[5] In cancer cells already burdened with high levels of DNA damage or replication stress, this checkpoint abrogation is catastrophic. The cells are forced to enter mitosis with unrepaired DNA, leading to widespread genomic instability, mitotic catastrophe, and ultimately, the induction of programmed cell death (apoptosis).[5]

In vitro studies have confirmed this mechanism, showing that treatment with Ceralasertib leads to cell cycle arrest, downregulation of proliferative signaling molecules, and increased levels of apoptotic markers such as cleaved PARP and caspase-3.[6] In some contexts, Ceralasertib can also induce cellular senescence.[17]

3.3 The Principle of Synthetic Lethality: Exploiting DDR Deficiencies

The strategic application of Ceralasertib is largely built upon the concept of synthetic lethality. This principle describes a situation where the loss of function of two different genes or pathways individually is viable, but their simultaneous loss is lethal to the cell. Ceralasertib exploits this by inhibiting ATR in cancer cells that have pre-existing deficiencies in other critical DDR pathways.[1]

The most well-established synthetic lethal partner for ATR is the ATM kinase. Tumors that have lost ATM function are unable to effectively respond to double-strand DNA breaks and become heavily reliant on the ATR pathway to manage the resulting replication stress.[4] In these ATM-deficient tumors, the pharmacological inhibition of ATR by Ceralasertib creates a state of profound DDR collapse, leading to selective and potent tumor cell killing.[1]

This therapeutic rationale is not limited to a single genotype. The versatility of Ceralasertib stems from its ability to target both genotype-defined vulnerabilities (e.g., ATM mutations) and phenotype-defined vulnerabilities. Many tumors that are proficient in ATM and other DDR pathways still exhibit a heightened dependency on ATR due to chronic, high levels of oncogene-induced replication stress (e.g., from MYC amplification, mutant RAS, or CCNE1 amplification).[2] This dual applicability significantly broadens the potential patient population that could benefit from Ceralasertib. It also implies that a successful biomarker strategy will likely require a multi-faceted approach, incorporating not only genomic sequencing to identify DDR gene mutations but also functional assays or expression signatures capable of quantifying the level of replication stress within a tumor.

4.0 Preclinical Evidence and Proof-of-Concept

4.1 In Vitro Antineoplastic Activity Across Tumor Types

The antineoplastic potential of Ceralasertib has been extensively validated in preclinical in vitro models. It has demonstrated potent, single-agent, growth-inhibitory activity across a broad panel of human solid and hematological cancer cell lines, with a study of 197 lines showing that 73 (37%) had an IC50​ of less than 1 µM.[16] This activity has been confirmed in specific tumor types under investigation, including gastric cancer and NSCLC cell lines.[6] While enhanced sensitivity is frequently observed in cell lines with defects in the ATM pathway, potent activity is not restricted to this genetic background, underscoring the importance of replication stress as a broader determinant of sensitivity.[16] Furthermore,

in vitro studies have consistently demonstrated that Ceralasertib acts synergistically with DNA-damaging chemotherapy agents, such as cisplatin and gemcitabine, and with ionizing radiation, significantly enhancing their cytotoxic effects.[8]

4.2 In Vivo Efficacy in Xenograft Models

The promising in vitro activity of Ceralasertib has been successfully translated into in vivo animal models. In mouse xenograft models derived from human cancer cell lines, chronic daily oral administration of Ceralasertib as a monotherapy resulted in significant, dose-dependent inhibition of tumor growth.[6] This monotherapy efficacy was most pronounced in xenograft models with ATM deficiency, providing in vivo proof-of-concept for the synthetic lethality hypothesis.[8]

The synergistic potential of Ceralasertib was also confirmed in vivo. When combined with carboplatin or ionizing radiation, Ceralasertib led to a significant enhancement of anti-tumor activity compared to either agent alone.[16] In some models, particularly ATM-deficient lung cancer xenografts treated with Ceralasertib and cisplatin, the combination therapy was able to resolve the tumors completely, a level of efficacy not achievable with either monotherapy.[17] These preclinical findings provided a strong rationale for advancing Ceralasertib into clinical trials investigating these combination strategies.

4.3 Pharmacodynamic Biomarkers of Target Engagement

A critical component of preclinical and clinical drug development is the identification of pharmacodynamic (PD) biomarkers that can confirm the drug is engaging its target and eliciting the intended biological response in tissue. For Ceralasertib, several key PD biomarkers have been established. In vivo studies demonstrated that oral dosing of Ceralasertib leads to a dose-dependent modulation of these markers within tumor tissue.[16]

The primary biomarker of direct target engagement is the inhibition of CHK1 phosphorylation (pCHK1).[3] Downstream markers of the intended cellular response include a significant increase in pan-nuclear staining for phosphorylated histone H2AX (

γH2AX), which serves as a sensitive indicator of DNA double-strand breaks and replication stress.[3] An increase in phosphorylated RAD50 (pRAD50) is also observed, which is indicative of a compensatory activation of the ATM pathway in response to the accumulation of DNA damage caused by ATR inhibition.[3] These biomarkers have proven invaluable, bridging preclinical models and human studies by allowing researchers to confirm on-target activity in tumor biopsies from patients enrolled in clinical trials.[4]

5.0 Clinical Pharmacokinetics and Metabolism

5.1 Absorption, Distribution, Metabolism, and Excretion (ADME) Profile

Ceralasertib is formulated for oral administration and demonstrates rapid absorption in humans. Clinical pharmacokinetic (PK) studies have consistently shown a time to maximum plasma concentration (Tmax​) of approximately 1 to 2 hours after dosing.[2] Preclinical studies in mice provide some insight into its distribution, suggesting that the drug is rapidly and extensively distributed to most tissues, with the notable exceptions of the brain and spinal cord, indicating that Ceralasertib has limited ability to cross the blood-brain barrier.[21]

Detailed information on the metabolism and excretion of Ceralasertib in humans is currently being formally investigated. A dedicated Phase I human ADME study (NCT06754761) is underway to definitively characterize these properties. This trial utilizes radiolabeled [14C]-Ceralasertib to precisely trace the drug's metabolic pathways, identify its major metabolites, determine its routes of excretion (urine and feces), and establish its absolute bioavailability.[23] Preclinical data from mouse models suggest that Ceralasertib may undergo saturable first-pass metabolism in the gut and liver, which results in dose-dependent bioavailability, with greater-than-proportional increases in plasma exposure observed at higher doses.[21] Whether this non-linear kinetic behavior is recapitulated in humans at clinical doses is an important question the ADME study will address.

5.2 Dose Proportionality and Half-Life

Available clinical data from Phase I studies suggest that Ceralasertib exhibits dose-proportional pharmacokinetics within the therapeutic dose range investigated.[2] Following oral absorption, plasma concentrations decline with a terminal half-life reported to be between 8 and 16 hours.[2] This pharmacokinetic profile is suitable for either once-daily (QD) or twice-daily (BID) dosing schedules, both of which have been explored in clinical trials.

5.3 Implications for Dosing Schedules (Continuous vs. Intermittent)

Early clinical experience, particularly from the Phase I PATRIOT trial, revealed a critical aspect of Ceralasertib's clinical pharmacology: the superiority of intermittent dosing over continuous daily dosing.[19] While continuous dosing was explored initially, it was associated with cumulative, dose-limiting hematological toxicity. In contrast, an intermittent schedule, such as administration for 14 consecutive days followed by a 14-day rest period within a 28-day cycle, was found to be significantly better tolerated.[19]

This clinical observation is mechanistically coherent with the drug's on-target activity. The ATR kinase is not only critical for cancer cell survival but also plays an essential role in managing the physiological replication stress inherent in healthy, highly proliferative tissues, most notably the hematopoietic stem and progenitor cells of the bone marrow. Continuous, uninterrupted inhibition of ATR in this compartment likely prevents these cells from adequately repairing endogenous DNA damage, leading to their depletion and the observed myelosuppression (thrombocytopenia, anemia, neutropenia).[10] The "drug holiday" provided by an intermittent schedule allows for the clearance of Ceralasertib from the system, restoring ATR function in healthy bone marrow cells and permitting their recovery and repopulation. Cancer cells, often characterized by defective cell-cycle checkpoints, are less able to recover during this off-treatment period. This differential recovery kinetic between healthy and malignant tissues effectively widens the therapeutic window, allowing for the administration of a biologically effective dose while managing on-target toxicity. This principle has since become a cornerstone of the dosing strategy for Ceralasertib in its ongoing clinical development program.

6.0 Clinical Efficacy and Development Program

The clinical development of Ceralasertib is characterized by a broad and ambitious program investigating its utility across a wide range of solid tumors, both as a monotherapy and as a combination agent. This program has progressed from early-phase dose-finding studies to a pivotal, potentially registrational Phase III trial. A summary of the major clinical trials is presented in Table 2.

Table 2: Summary of Major Clinical Trials Investigating Ceralasertib

Trial ID (Name)	Phase	Indication(s)	Combination Agent(s)	Status	Key Objective / Finding
NCT02223923 (PATRIOT)	1	Advanced Solid Tumors	Monotherapy	Completed	Established monotherapy RP2D (160 mg BID, intermittent). Showed durable responses in biomarker-selected patients (e.g., ARID1A-loss).
NCT05450692 (LATIFY)	3	NSCLC (post-IO/chemo)	Durvalumab	Recruiting	Pivotal efficacy and safety study comparing Ceralasertib + Durvalumab versus standard-of-care docetaxel.
NCT03334617 (HUDSON)	2 (Umbrella)	NSCLC (post-IO/chemo)	Durvalumab, Olaparib, etc.	Active, not recruiting	Demonstrated a strong efficacy signal for the Ceralasertib + Durvalumab combination, especially in patients with ATM-altered tumors.
NCT03780608	2	Advanced Gastric Cancer	Durvalumab	Results Published	Showed promising ORR (22.6%) and a significant PFS benefit in patients with ATM loss and/or high HRD signatures.
NCT02630199	1	Refractory Solid Tumors	Paclitaxel	Results Published	Established safety and tolerability of the combination. Demonstrated a high ORR (33.3%) in melanoma patients refractory to immunotherapy.
NCT04564027 (PLANETTE)	2a	ATM-altered Solid Tumors	Monotherapy	Results Published	Assessed monotherapy activity in a biomarker-selected population; responses were limited, suggesting combination approaches may be superior.
NCT03682289	2	Solid Tumors	Monotherapy, Olaparib, Durvalumab	Recruiting	Basket trial exploring Ceralasertib in various combinations across multiple tumor types and biomarker-defined cohorts.
NCT06754761	1	Solid Tumors	Monotherapy	Recruiting	Dedicated human ADME study to characterize the full pharmacokinetic profile of Ceralasertib.

6.1 Monotherapy in Advanced Solid Tumors: The PATRIOT Trial

The first-in-human PATRIOT trial (NCT02223923) was foundational for Ceralasertib's development, establishing its safety, tolerability, and preliminary efficacy as a single agent.[19] The study determined the recommended Phase II dose (RP2D) for monotherapy to be 160 mg administered twice daily on an intermittent schedule of 14 days on, followed by 14 days off.[19]

While the overall objective response rate (ORR) across all patients was modest at 8% (5 confirmed partial responses out of 66 evaluable patients), the trial's significance lies in the nature of these responses. Stable disease (SD) was achieved in 52% of patients, and for those who achieved SD or better, 68% remained on study for at least four months, indicating meaningful disease control.[11] Critically, durable and deep responses were observed almost exclusively in patients whose tumors harbored genomic alterations hypothesized to confer sensitivity to ATR inhibition. The most striking example was a patient with clear cell ovarian carcinoma with an

ARID1A mutation who experienced a durable response lasting over five years.[11] Other responders had tumors with defects in genes such as

BRIP1, PALB2, and MRE11A, or high tumor inflammation.[11] These results provided the first clinical validation of a biomarker-driven strategy for Ceralasertib monotherapy.

6.2 Combination Therapy Regimens: A Multi-pronged Strategy

6.2.1 Synergy with Chemotherapy: Paclitaxel and Carboplatin

Building on strong preclinical rationale, Ceralasertib has been evaluated in combination with cytotoxic chemotherapies. A Phase I trial (NCT02630199) combining Ceralasertib with weekly paclitaxel in patients with refractory solid tumors found the combination to be well-tolerated.[2] This study produced a notable efficacy signal, particularly in a cohort of 33 melanoma patients who had previously progressed on anti-PD-1 immunotherapy, where the combination achieved an ORR of 33.3%.[2]

Similarly, a Phase I study combined Ceralasertib with the platinum agent carboplatin in patients with advanced solid tumors.[4] This trial successfully established a safe and tolerable RP2D for the combination and demonstrated preliminary signs of antitumor activity. Two patients achieved confirmed partial responses, and both had tumors with biomarkers of potential sensitivity: absent or low expression of ATM or SLFN11 protein.[32] Stable disease was observed in 53% of response-evaluable patients.[32]

6.2.2 Combination with PARP Inhibitors: The Olaparib Studies

The combination of ATR inhibitors and poly(ADP-ribose) polymerase (PARP) inhibitors is a rational strategy designed to induce a deeper state of synthetic lethality by simultaneously targeting two critical nodes of the DDR pathway. Ceralasertib is being actively investigated in combination with the PARP inhibitor olaparib in several trials, including studies in patients with triple-negative breast cancer and other advanced solid tumors with specific genomic alterations.[12] These trials aim to overcome both intrinsic and acquired resistance to PARP inhibitor monotherapy.

6.2.3 Immuno-Oncology Combinations: Durvalumab in NSCLC and Gastric Cancer

The combination of Ceralasertib with the anti-PD-L1 immune checkpoint inhibitor durvalumab has emerged as the most promising and advanced area of its clinical development. The rationale is that by inducing DNA damage and genomic instability, Ceralasertib may increase tumor antigenicity and stimulate anti-tumor immune responses, thereby synergizing with immunotherapy.

In a Phase II trial (NCT03780608) for patients with refractory advanced gastric cancer (AGC), the combination of Ceralasertib and durvalumab demonstrated an ORR of 22.6% and a disease control rate (DCR) of 58.1%.[35] More importantly, exploratory biomarker analysis revealed a profound benefit in a molecularly defined subgroup. Patients whose tumors had ATM protein loss and/or a high mutational signature of homologous repair deficiency (sig. HRD) experienced a median progression-free survival (PFS) of 5.60 months, compared to just 1.65 months in patients without these biomarkers.[35]

This strong signal was amplified in the Phase II umbrella HUDSON trial (NCT03334617) in patients with advanced NSCLC who had progressed after both platinum chemotherapy and immunotherapy.[38] Among several novel combination arms, the Ceralasertib plus durvalumab cohort demonstrated the greatest clinical benefit. The ORR was 13.9% versus 2.6% for all other pooled regimens. Median PFS was 5.8 months versus 2.7 months, and median overall survival (OS) was a remarkable 17.4 months versus 9.4 months.[38] The benefit was even more pronounced in the biomarker-matched cohort of patients with

ATM-altered tumors, who achieved an ORR of 26.1%.[38]

6.3 Analysis of the Phase III LATIFY Trial in Non-Small Cell Lung Cancer

The compelling efficacy and survival data from the HUDSON trial provided the direct impetus for the design and launch of the pivotal Phase III LATIFY trial (NCT05450692).[39] This large, randomized, open-label, multicenter study is currently enrolling patients with advanced or metastatic NSCLC whose disease has progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy—a population with a significant unmet medical need and limited effective treatment options.

The trial is randomizing 594 patients in a 1:1 ratio to receive either the experimental combination of Ceralasertib plus durvalumab or the standard-of-care second- or third-line agent, docetaxel.[40] The primary endpoint is overall survival. This study represents a high-stakes, high-reward endeavor for AstraZeneca. It is a direct result of the company's strategic decision to act decisively on the strong signal observed in the Phase II HUDSON study. Rather than pursuing a smaller, biomarker-restricted population, the LATIFY trial targets a broader, more common clinical scenario in oncology. A positive outcome would not only lead to regulatory approval but would also establish a new standard of care for a large patient population, validating the hypothesis that ATR inhibition can overcome resistance to immunotherapy. The results of this trial, anticipated in 2025, are eagerly awaited and will be a defining moment for Ceralasertib and the broader field of DDR inhibitors.

6.4 Biomarkers for Patient Selection: ATM, ARID1A, and Replication Stress Signatures

Across the entire clinical program, a consistent theme is the search for and validation of predictive biomarkers to identify patients most likely to respond to Ceralasertib. The data strongly support the enrichment of responses in tumors with specific genomic alterations.

• ATM Deficiency: Loss of ATM function, identified either by pathogenic mutation or by loss of protein expression via immunohistochemistry (IHC), has consistently emerged as a strong predictor of sensitivity, particularly to Ceralasertib-based combinations.[32]
• ARID1A Loss: The PATRIOT trial highlighted the exceptional sensitivity of tumors with mutations in ARID1A, a member of the SWI/SNF chromatin remodeling complex, suggesting that defects in this pathway may also create a synthetic lethal dependency on ATR.[11]
• HRD Signatures: In gastric cancer, a high mutational signature associated with homologous repair deficiency (HRD) was predictive of a significant PFS benefit, broadening the potential biomarker beyond single-gene alterations.[35]

The collective evidence suggests that the optimal biomarker strategy may be a composite one, incorporating both specific gene alterations and broader functional signatures of genomic instability or replication stress.

Table 3: Summary of Efficacy Outcomes for Ceralasertib Across Key Trials and Indications

Trial (NCT ID)	Indication	Patient Population	Combination Agent	N	ORR (%)	DCR (%)	Median PFS (months)	Median OS (months)	Key Biomarker Finding
PATRIOT (NCT02223923)	Advanced Solid Tumors	Refractory	Monotherapy	67	8	60	-	-	Durable responses in patients with ARID1A loss and other DDR defects.
NCT02630199	Melanoma	Post-Immunotherapy	Paclitaxel	33	33.3	60.6	3.6	7.4	High response rate in an IO-refractory population.
NCT03780608	Gastric Cancer	Refractory	Durvalumab	31	22.6	58.1	3.0	6.7	Significant PFS benefit (5.6 vs 1.65 mos) in patients with ATM loss / high HRD.
HUDSON (NCT03334617)	NSCLC	Post-IO/Chemo	Durvalumab	79	13.9	-	5.8	17.4	ORR of 26.1% and superior survival in ATM-altered cohort.

7.0 Clinical Safety and Tolerability

7.1 Consolidated Safety Profile from Clinical Trials

The safety profile of Ceralasertib has been characterized across numerous Phase I and II clinical trials, involving hundreds of patients treated with both monotherapy and various combination regimens. The most consistent and clinically significant adverse events are hematologic in nature, which is an expected on-target toxicity given the essential role of ATR in maintaining the genomic integrity of highly proliferative hematopoietic cells.[2] Non-hematologic adverse events are also common, though typically of lower severity.

7.2 Dose-Limiting Toxicities and Management Strategies

Across multiple studies, the primary dose-limiting toxicity (DLT) for Ceralasertib, both as a monotherapy and in combination, is thrombocytopenia (low platelet count).[10] Grade 3 or 4 anemia and neutropenia are also very frequent and contribute to the overall myelosuppressive profile of the drug.[2]

The management of these hematologic toxicities is a key aspect of clinical practice with Ceralasertib. Strategies include proactive monitoring of complete blood counts, dose interruptions to allow for marrow recovery, and subsequent dose reductions.[35] In some cases, supportive care measures such as blood or platelet transfusions may be required.[45] The most effective mitigation strategy identified in early development was the shift from continuous to intermittent dosing schedules, which provides a crucial recovery period for the bone marrow between treatment cycles.[19]

7.3 Adverse Event Profile in Monotherapy vs. Combination Settings

While hematologic toxicity is the hallmark of Ceralasertib's safety profile in all settings, the incidence and severity of adverse events are often amplified when it is combined with other myelosuppressive agents. For example, in combination with paclitaxel, Grade ≥3 neutropenia was reported in 68% of patients, a rate higher than typically seen with Ceralasertib monotherapy.[2]

Common non-hematologic treatment-emergent adverse events of any grade include fatigue, nausea, anorexia (decreased appetite), and vomiting.[45] These are generally manageable with standard supportive care. The overall safety profile in combination with the immunotherapy agent durvalumab has been described as manageable and consistent with the known profiles of each individual drug, with no new or unexpected safety signals emerging.[38] A summary of the most frequent Grade ≥3 adverse events from key combination trials is presented in Table 4.

Table 4: Consolidated Safety Profile: Common Treatment-Emergent Adverse Events (Grade ≥3)

Adverse Event	Frequency (%) (Grade ≥3)	Trial Context	Source(s)
Anemia	39	Ceralasertib + Carboplatin	28
	44	Ceralasertib + Paclitaxel	2
	35.5	Ceralasertib + Durvalumab (Gastric Cancer)	45
	33.3	Ceralasertib + Durvalumab (Melanoma)	44
Thrombocytopenia	36	Ceralasertib + Carboplatin	28
	37	Ceralasertib + Paclitaxel	2
	35.5	Ceralasertib + Durvalumab (Gastric Cancer)	45
Neutropenia / Leukopenia	25	Ceralasertib + Carboplatin	28
	68	Ceralasertib + Paclitaxel	2

8.0 Regulatory Status and Future Directions

8.1 Current FDA and EMA Status

Ceralasertib is an investigational new drug and has not received marketing approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication.[10] It remains in active clinical development. The EMA's Paediatric Committee (PDCO) has issued a decision granting a product-specific waiver for a Paediatric Investigation Plan (PIP) for Ceralasertib in the treatment of lung carcinoma (small cell and non-small cell).[5] This decision, dated March 11, 2022, waives the requirement for pediatric studies in all age groups for this indication, allowing the adult development program to proceed without parallel pediatric investigations at this time.[49]

8.2 The Competitive Landscape of ATR Inhibitors

The therapeutic potential of ATR inhibition has attracted significant interest, and several molecules are in clinical development, creating a competitive landscape. Besides Ceralasertib (AZD6738), other notable clinical-stage ATR inhibitors include berzosertib (M6620, formerly VX-970) and elimusertib (BAY 1895344).[50]

• Berzosertib has been extensively studied in numerous Phase I and II trials, often in combination with chemotherapy.[53] However, its development has faced challenges, with at least one Phase II trial in small-cell lung cancer being discontinued due to a low probability of meeting its primary objective, leading to a reassessment of its path forward in that indication.[55]
• Elimusertib is another potent, orally available ATR inhibitor. Preclinical head-to-head comparisons in certain cancer models, such as lymphoma and glioblastoma, have suggested that elimusertib may be more potent than Ceralasertib.[56] Additionally, preclinical data indicate that elimusertib may have a greater capacity to penetrate the blood-brain barrier, which could be an advantage for treating primary or metastatic brain tumors.[22]

Despite the presence of these competitors, Ceralasertib currently appears to be a leading candidate, distinguished by the advanced stage of its Phase III LATIFY trial and the particularly robust and compelling clinical data generated from its combination studies with the immune checkpoint inhibitor durvalumab.

8.3 Future Outlook and Unanswered Questions

The future trajectory of Ceralasertib is heavily dependent on the outcome of the pivotal LATIFY trial in NSCLC. A positive result would likely lead to regulatory submissions and could establish Ceralasertib as a new standard of care, validating the entire therapeutic concept of combining DDR inhibition with immunotherapy to overcome resistance.

Several key questions remain that will shape its ultimate role in oncology. First, the development of a robust and commercially viable companion diagnostic is paramount. While biomarkers like ATM and ARID1A loss are promising, a more refined and validated biomarker strategy is needed to precisely identify the optimal patient populations for both monotherapy and combination therapy. Second, a deeper understanding of the molecular mechanisms underlying the synergy between ATR inhibition and immunotherapy is required to guide future combination strategies and potentially identify new biomarkers. Finally, continued efforts to optimize dosing schedules and manage hematologic toxicity will be crucial for improving the therapeutic index, particularly when Ceralasertib is combined with other myelosuppressive agents.

9.0 Conclusion and Strategic Recommendations

9.1 Synthesis of Ceralasertib's Profile: Strengths and Weaknesses

Ceralasertib has emerged as a leading clinical-stage ATR inhibitor with a well-defined profile of strengths and challenges.

Strengths:

• Potent and Selective Mechanism: It is a highly potent, orally bioavailable inhibitor with excellent selectivity for ATR over other kinases, which is fundamental to its therapeutic potential.
• Strong Mechanistic Rationale: Its development is supported by a robust scientific rationale based on the principles of synthetic lethality and chemosensitization/radiosensitization.
• Validated Monotherapy Activity: The PATRIOT trial provided clinical proof-of-concept that Ceralasertib monotherapy can produce durable responses in patients with specific biomarker-defined tumors.
• Exceptional Combination Potential: The drug has demonstrated promising synergy with multiple classes of anticancer agents, with the combination data with the PD-L1 inhibitor durvalumab being particularly strong and compelling.
• Advanced Clinical Development: With a pivotal Phase III trial ongoing, Ceralasertib is one of the most advanced ATR inhibitors in the global pipeline, giving it a potential first-to-market advantage in key indications.

Weaknesses and Challenges:

• On-Target Hematologic Toxicity: Significant myelosuppression (thrombocytopenia, anemia, neutropenia) is the primary safety concern and dose-limiting factor, requiring careful patient monitoring and schedule optimization.
• Limited Monotherapy Activity in Unselected Populations: As expected for a targeted agent, its efficacy as a single agent is limited in patients without a clear biomarker of dependency.
• Complex and Evolving Biomarker Landscape: While several promising biomarkers have been identified (ATM, ARID1A, HRD), a definitive, validated companion diagnostic strategy has not yet been established, which will be essential for its optimal clinical use.

9.2 Recommendations for Future Clinical Investigation and Biomarker Development

Based on the comprehensive analysis of the available data, several strategic recommendations can be made for the continued development of Ceralasertib.

1. Prioritize Biomarker Validation: The highest priority should be the validation of a robust, multi-modal biomarker signature for patient selection. This should move beyond single-gene analysis to incorporate a composite panel that may include:

• Genomic sequencing for pathogenic alterations in key DDR genes (ATM, ARID1A, BRCA1/2, etc.).
• Immunohistochemistry for protein loss (e.g., ATM, ARID1A).
• Functional genomic signatures that quantify replication stress or homologous repair deficiency (HRD). This validated signature will be critical for the success of future trials and for guiding clinical practice upon potential approval.

2. Deepen Mechanistic Understanding of IO Synergy: The striking results from the durvalumab combination studies warrant a dedicated research effort to fully elucidate the underlying immunomodulatory mechanisms. This should include serial tumor biopsies and peripheral blood analyses in ongoing trials to characterize changes in the tumor microenvironment, T-cell receptor clonality, and innate immune signaling pathways. Understanding how Ceralasertib re-sensitizes tumors to immunotherapy will be key to optimizing its use and identifying the next generation of rational IO combinations.
3. Explore Novel Combination Strategies: While the current combination strategies are promising, the fundamental mechanism of Ceralasertib suggests potential synergy with other classes of agents. Future early-phase trials should explore combinations with inhibitors of other cell-cycle checkpoints (e.g., WEE1 inhibitors) or other targeted agents that induce replication stress, aiming to create deeper and more durable responses.

Works cited

1. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent | Journal of Medicinal Chemistry - ACS Publications, accessed August 13, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01187
2. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8974415/
3. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib | Cancer Research - AACR Journals, accessed August 13, 2025, https://aacrjournals.org/cancerres/article/82/6/1140/682067/ATR-Inhibitor-AZD6738-Ceralasertib-Exerts
4. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in ..., accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9401487/
5. Ceralasertib | C20H24N6O2S | CID 121596701 - PubChem, accessed August 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ceralasertib
6. Ceralasertib | CAS#1352226-88-0 | ART inhibitor - MedKoo Biosciences, accessed August 13, 2025, https://www.medkoo.com/products/5275
7. Definition of ceralasertib - NCI Drug Dictionary, accessed August 13, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ceralasertib
8. AZD 6738 (Ceralasertib, CAS Number: 1352226-88-0) | Cayman Chemical, accessed August 13, 2025, https://www.caymanchem.com/product/21035/azd-6738
9. AZD 6738 | CAS 1352226-88-0 | Cayman Chemical | Biomol.com, accessed August 13, 2025, https://www.biomol.com/products/chemicals/biochemicals/azd-6738-cay21035-1
10. Ceralasertib - NCI - Division of Cancer Treatment and Diagnosis, accessed August 13, 2025, https://dctd.cancer.gov/drug-discovery-development/reagents-materials/formulary/about/agents/ceralasertib
11. Durable responses to ATR inhibition with ceralasertib in tumors ... - JCI, accessed August 13, 2025, https://www.jci.org/articles/view/175369
12. Clinical Trials Using Ceralasertib - NCI - National Cancer Institute, accessed August 13, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/ceralasertib?pn=1
13. Oncology – AstraZeneca - Portfolio & Pipeline, accessed August 13, 2025, https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html
14. Ceralasertib - Wikipedia, accessed August 13, 2025, https://en.wikipedia.org/wiki/Ceralasertib
15. Ceralasertib (AZD6738) | ATR Inhibitor - MedchemExpress.com, accessed August 13, 2025, https://www.medchemexpress.com/AZD6738.html
16. AZD6738 - AstraZeneca Open Innovation, accessed August 13, 2025, https://openinnovation.astrazeneca.com/preclinical-research/preclinical-molecules/azd6738.html
17. Ceralasertib | MedChemExpress, accessed August 13, 2025, https://file.medchemexpress.com/batch_PDF/HY-19323/Ceralasertib-DataSheet-MedChemExpress.pdf
18. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/35078817/
19. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10786692/
20. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in ..., accessed August 13, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401487/
21. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice - Johns Hopkins University, accessed August 13, 2025, https://pure.johnshopkins.edu/en/publications/dose-dependent-bioavailability-and-tissue-distribution-of-the-atr
22. The Pharmacokinetics, Toxicity, and Immunological Effects of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitors AZD6738 (ceralasertib) and BAY-1895344 (elimusertib) - D-Scholarship@Pitt, accessed August 13, 2025, http://d-scholarship.pitt.edu/42387/
23. Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib - ClinicalTrials.Veeva, accessed August 13, 2025, https://ctv.veeva.com/study/human-adme-study-of-14c-ceralasertib-azd6738-and-absolute-bioavailability-of-ceralasertib
24. Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of ... - ClinicalTrials.gov, accessed August 13, 2025, https://clinicaltrials.gov/study/NCT06754761
25. Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice | Request PDF - ResearchGate, accessed August 13, 2025, https://www.researchgate.net/publication/358043874_Dose-dependent_bioavailability_and_tissue_distribution_of_the_ATR_inhibitor_AZD6738_ceralasertib_in_mice
26. Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice - PMC - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8829872/
27. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/37934611/
28. aacrjournals.org, accessed August 13, 2025, https://aacrjournals.org/clincancerres/article/27/19/5213/671706/Ceralasertib-AZD6738-an-Oral-ATR-Kinase-Inhibitor#:~:text=The%20most%20common%20treatment%2Demergent,%2C%20and%20neutropenia%20(25%25).
29. Ceralasertib shows potential in treating cancer, ICR study finds - Clinical Trials Arena, accessed August 13, 2025, https://www.clinicaltrialsarena.com/news/ceralasertib-cancer-icr-study/
30. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer - AACR Journals, accessed August 13, 2025, https://aacrjournals.org/clincancerres/article/27/17/4700/671664/Phase-I-Study-of-Ceralasertib-AZD6738-a-Novel-DNA
31. Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199). - ASCO, accessed August 13, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT310657
32. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study - AACR Journals, accessed August 13, 2025, https://aacrjournals.org/clincancerres/article/27/19/5213/671706/Ceralasertib-AZD6738-an-Oral-ATR-Kinase-Inhibitor
33. Ceralasertib Recruiting Phase 2 Trials for Breast Neoplasms Other | DrugBank Online, accessed August 13, 2025, https://go.drugbank.com/drugs/DB14917/clinical_trials?conditions=DBCOND0028011&phase=2&purpose=other&status=recruiting
34. Search for: Other terms: AZD6738 OR Ceralasertib, Phase: 2 | Card Results | ClinicalTrials.gov, accessed August 13, 2025, https://clinicaltrials.gov/ct2/results?cond=&term=AZD6738+OR+Ceralasertib&cntry=&state=&city=&dist=&Search=Search&phase=1
35. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/35790315/
36. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. - ASCO, accessed August 13, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT371390
37. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer - ResearchGate, accessed August 13, 2025, https://www.researchgate.net/publication/361823482_Phase_II_study_of_ceralasertib_AZD6738_in_combination_with_durvalumab_in_patients_with_advanced_gastric_cancer
38. Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic NSCLC Following Prior Failure to Anti-PD1/PD-L1 and Platinum-Doublet Therapy | ESMO, accessed August 13, 2025, https://www.esmo.org/oncology-news/efficacy-safety-and-translational-data-from-durvalumab-plus-ceralasertib-in-advanced-metastatic-nsclc-following-prior-failure-to-anti-pd1-pd-l1-and-platinum-doublet-therapy
39. Ceralasertib Recruiting Phase 3 Trials for Non-Small Cell Lung Carcinoma Treatment, accessed August 13, 2025, https://go.drugbank.com/drugs/DB14917/clinical_trials?conditions=DBCOND0030527&phase=3&purpose=treatment&status=recruiting
40. Study Details | A Phase III Study of Ceralasertib Plus Durvalumab ..., accessed August 13, 2025, https://clinicaltrials.gov/study/NCT05450692
41. A Phase III Study of Ceralasertib plus Durvalumab versus Docetaxel in Patients with Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy - LATIFY - AstraZeneca Clinical Trials, accessed August 13, 2025, https://www.astrazenecaclinicaltrials.com/study/D533BC00001/
42. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: A phase I study - MD Anderson Cancer Center, accessed August 13, 2025, https://mdanderson.elsevierpure.com/en/publications/ceralasertib-azd6738-an-oral-atr-kinase-inhibitor-in-combination-
43. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy - PubMed, accessed August 13, 2025, https://pubmed.ncbi.nlm.nih.gov/34710570/
44. Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy. - ASCO Publications, accessed August 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9514
45. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer, accessed August 13, 2025, https://jitc.bmj.com/content/10/7/e005041
46. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. - ASCO Publications, accessed August 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4045
47. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9258491/
48. CERALASERTIB - Inxight Drugs, accessed August 13, 2025, https://drugs.ncats.io/drug/85RE35306Z
49. EMEA-003127-PIP01-21 - paediatric investigation plan - EMA - European Union, accessed August 13, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003127-pip01-21
50. Molecular Pathways: Targeting ATR in Cancer Therapy - AACR Journals, accessed August 13, 2025, https://aacrjournals.org/clincancerres/article/21/21/4780/175165/Molecular-Pathways-Targeting-ATR-in-Cancer
51. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents - AACR Journals, accessed August 13, 2025, https://aacrjournals.org/mct/article/20/8/1431/673284/Novel-and-Highly-Potent-ATR-Inhibitor-M4344-Kills
52. Dose-Dependent Bioavailability, Absorption-Rate Limited Elimination, and Tissue Distribution of the ATR Inhibitor BAY-1895344 (elimusertib) in Mice - PubMed Central, accessed August 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10082586/
53. Berzosertib - Merck KGaA - AdisInsight - Springer, accessed August 13, 2025, https://adisinsight.springer.com/drugs/800037997
54. Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors | JCO Precision Oncology - ASCO Publications, accessed August 13, 2025, https://ascopubs.org/doi/10.1200/PO-25-00055
55. Pipeline Moves: Merck KGaA's berzosertib progression shot in small-cell lung cancer reviewed after Phase II discontinued - Clinical Trials Arena, accessed August 13, 2025, https://www.clinicaltrialsarena.com/features/berzosertib-lung-cancer-trial-discontinued/
56. The ATR inhibitor elimusertib exhibits anti-lymphoma ... - bioRxiv, accessed August 13, 2025, https://www.biorxiv.org/content/10.1101/2023.02.10.528011v1.full.pdf
57. DNAR-07. ATR INHIBITORS IN COMBINATION WITH RADIATION AND TEMOZOLOMIDE INCREASE CELL DEATH OF PATIENT-DERIVED GLIOBLASTOMA CELLS | Neuro-Oncology | Oxford Academic, accessed August 13, 2025, https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii118/7890605
58. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and ..., accessed August 13, 2025, https://www.biorxiv.org/content/10.1101/2023.02.10.528011v1